[EN] NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX LIANTS DES RÉCEPTEURS SIGMA 2 ET LEUR PROCÉDÉ D'UTILISATION
申请人:TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
公开号:WO2016183150A1
公开(公告)日:2016-11-17
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.
[EN] NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE<br/>[FR] NOUVEAUX MODULATEURS DE L'ACTIVITÉ DU RÉCEPTEUR 7 DE LA 5-HYDROXYTRYPTAMINE ET LEUR PROCÉDÉ D'UTILISATION
申请人:UNIV TEMPLE
公开号:WO2014164756A1
公开(公告)日:2014-10-09
Pharmaceiiticai compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
NOVEL 5-HYDROXYTRYPTAMINE RECEPTOR 7 ACTIVITY MODULATORS AND THEIR METHOD OF USE
申请人:TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
公开号:US20160016941A1
公开(公告)日:2016-01-21
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
5-hydroxytryptamine receptor 7 activity modulators and their method of use
申请人:TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
公开号:US10239868B2
公开(公告)日:2019-03-26
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.
NOVEL SIGMA-2 RECEPTOR BINDERS AND THEIR METHOD OF USE
申请人:Temple University-Of The Commonwealth System of Higher Education
公开号:US20180221365A1
公开(公告)日:2018-08-09
Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of sigma-2 receptor activity.